XML 19 R30.htm IDEA: XBRL DOCUMENT v2.4.0.8
License and Collaboration Agreements - Additional Information (Detail) (USD $)
In Millions, unless otherwise specified
 6 Months Ended 0 Months Ended 6 Months Ended 1 Months Ended 2 Months Ended 6 Months Ended 1 Months Ended 6 Months Ended 12 Months Ended 0 Months Ended 0 Months Ended 6 Months Ended 3 Months Ended 6 Months Ended
Jun. 30, 2014
Sep. 25, 2013
MOVANTIK [Member]
Jun. 30, 2014
MOVANTIK [Member]
US and EU Commercial Launch [Member]
Jun. 30, 2014
Roche [Member]
MIRCERA [Member]
Feb. 29, 2012
Roche [Member]
MIRCERA [Member]
Performance-based Milestone Payments [Member]
Feb. 29, 2012
Roche [Member]
MIRCERA [Member]
Upfront Payment Arrangement in 2007 [Member]
Jun. 30, 2014
Roche [Member]
PEGASYS [Member]
Jun. 30, 2014
Roche [Member]
PEGASYS and MIRCERA [Member]
Jun. 30, 2014
Baxter Healthcare [Member]
BAX 855 (Hemophilia) [Member]
Jun. 30, 2014
Amgen, Inc. [Member]
Jun. 30, 2013
Bayer Healthcare LLC [Member]
Jun. 30, 2014
Bayer Healthcare LLC [Member]
Jun. 30, 2014
Bayer Healthcare LLC [Member]
Performance-based Milestone Payments [Member]
Dec. 31, 2007
Bayer Healthcare LLC [Member]
Upfront Payment Arrangement in 2007 [Member]
Sep. 16, 2013
AstraZeneca AB [Member]
Sep. 16, 2013
AstraZeneca AB [Member]
Sep. 16, 2013
AstraZeneca AB [Member]
January 15, 2015 [Member]
Sep. 16, 2013
AstraZeneca AB [Member]
January 15, 2016 [Member]
Sep. 16, 2013
AstraZeneca AB [Member]
January 15, 2017 [Member]
Sep. 16, 2013
AstraZeneca AB [Member]
January 15, 2018 [Member]
Sep. 16, 2013
AstraZeneca AB [Member]
MOVANTIK [Member]
Jun. 30, 2014
AstraZeneca AB [Member]
MOVANTIK [Member]
Sep. 16, 2013
AstraZeneca AB [Member]
MOVANTIK [Member]
Jun. 30, 2014
AstraZeneca AB [Member]
MOVANTIK [Member]
Pre-approval Cardiovascular Safety Study Not Required [Member]
Jun. 30, 2014
AstraZeneca AB [Member]
Movantik Fixed-dose Combination Program [Member]
Jun. 30, 2014
Ophthotech Corporation [Member]
Fovista [Member]
Jun. 30, 2014
Other [Member]
Jun. 30, 2014
Other [Member]
Deferred Revenue Arrangement [Line Items]                                                        
Potential aggregate future additional payments for development milestones $ 146.3               $ 28.0     $ 50.0                           $ 9.5   $ 61.8
Contingent payments receivable based on development events regulatory to be pursued and completed solely by others     140.0                                     175.0   35.0 75.0      
Contingent payments received   25.0                                                    
Contingent repayments of payment received                               70.0 10.0 10.0 20.0 30.0                
Accrued interest rate                             0.045                          
Reduction on non-U.S. royalty for repayment                                         50.00%              
Potential reduction in US royalty rate for repayment                                         2.00%              
Percentage of post approval study costs to repay                                         33.00%              
Maximum potential reduction in royalties                                             35.0          
Deferred revenue       13.4     7.7 5.7 0 31.7   21.6                           19.6    
Received upfront and milestone payments         22.00 5.00             30.00 40.00                       19.75    
Consideration received for product delivered in 2013       18.6                                                
Performance milestone payment to Bayer                     10.0                                  
Royalty expiration period                                                   10 years    
Milestone payment received from transfers of manufacturing technology                                                     $ 9.0